BrainsWay heads into its third-quarter report with a split personality. The business told a story of acceleration last quarter, with record system shipments, a fatter EBITDA margin and its first guidance raise of the year. The stock has gone the other way, falling roughly 30% since that report while the S&P 500 slipped about 3%. Shares at $11.09 sit just above their post-earnings low of $11.00 and well below the 200-day moving average near $13.91. That gap between operating momentum and market reception is what makes the November 10 report, due before the open, worth close attention.
The Street expects earnings of $0.12 a share on revenue of $18.3 million. That would be about 35% revenue growth from the $13.5 million posted a year ago and a 50% jump in EPS from $0.08. On the top line, that extends the steady sequential climb from $15.5 million in the first quarter and $17.1 million in the second. The EPS estimate is a notch below last quarter's $0.14, however. That suggests analysts are building in the heavier spending management flagged, including higher G&A from professional and administrative fees and R&D rising to support PTSD and alcohol use disorder programs.
The guidance math is where this report gets interesting. Management raised full-year revenue guidance to $68 million to $70 million from $66 million to $68 million, after reaffirming the lower range twice. Consensus of $68.5 million sits in the lower half of the new range. First-half revenue totaled $32.6 million, so a third quarter at $18.3 million would leave only about $17.6 million needed in the fourth quarter to reach the Street's annual figure. That would be a sequential decline for a company that has grown every quarter. In other words, the full-year outlook looks conservative if the third quarter lands where expected. A clean beat would make a second raise a natural question, while a merely in-line quarter paired with an unchanged range could read as caution. On profitability, adjusted EBITDA guidance of $13 million to $14 million implies the second half needs roughly $6.7 million to $7.7 million. That is broadly consistent with holding near the second quarter's $3.5 million pace, so the 20% margin from last quarter now needs to look repeatable rather than a one-off.
The operating indicators behind the revenue matter as much as the headline. Shipments rose from 90 systems a year ago to 125 last quarter, and the installed base approached 1,960. Remaining performance obligations climbed to $80.4 million, giving management visibility into 2027. Continued growth in shipments and backlog would support the claim that demand is broadening. A stall would challenge it, particularly given the lease-heavy model that turns placements into future revenue. Gross margin has held near 75% for four straight quarters, and any slippage would stand out. Reimbursement for the accelerated SWIFT protocol has already reached about 57 million covered lives, ahead of the year-end target, so further gains there would help explain utilization trends.
The newer catalysts deserve an update too. Management filed with the FDA for a comorbid PTSD and depression indication and expects clearance by year-end, and any timing change would be meaningful. The ProLiVarex soft launch through the VA was described as early, with the following 90 days meant to define its metrics. This report is the first chance to see whether that rollout has substance.
Sentiment has soured sharply, swinging from mildly bullish before the last report to clearly bearish now. That lowers the emotional bar but does not predict the outcome. The central issue is simple: BrainsWay needs to show that last quarter's margin leap and guidance raise marked the start of a trend, with shipments, backlog and EBITDA all continuing to rise even as spending climbs. If it does, the stock's slide looks disconnected from the business. If it does not, the market's skepticism will look justified.